Anyone who knows their $PAB history willl know SM6 was a debacle - missing the comercialisation stage and putting the cart before the horse. SM6 was and remains a ground-breaking cancer killer but was/is unable to be manufactured at a commercial level. See if China can do it...but...
...they have learnt their lesson with DX1
A stable cell line is the key to commercialisation. Without that there is nothing.
The biggest take of this ann is the de-risking of a small cap company to give her wings to fly.
$PAB ....is only a matter of time
PAB Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
